Marshall Wace, LLP Avadel Pharmaceuticals PLC Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $2.95 Million - $4.47 Million	-306,218 Reduced 66.45%	154,585 $2.18 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $1.53 Million - $2.37 Million	-148,223 Reduced 24.34%	460,803 $4.75 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $2.55 Million - $4.96 Million	301,151 Added 97.82%	609,026 $10 Million
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $1.97 Million - $3.06 Million	307,875 New	307,875 $2.82 Million
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $87,789 - $570,219	-82,046 Reduced 88.1%	11,081 $27,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $508,473 - $772,022	93,127 New	93,127 $636,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $660,288 - $1.04 Million	-131,270 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$5.02 - $8.98 $658,975 - $1.18 Million	131,270 New	131,270 $661,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $626M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.